Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Profit After Tax (2021 - 2025)

Historic Profit After Tax for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to -$2.0 million.

  • InMed Pharmaceuticals' Profit After Tax rose 2123.48% to -$2.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.7 million, marking a year-over-year increase of 356.73%. This contributed to the annual value of -$8.2 million for FY2025, which is 649.35% down from last year.
  • Per InMed Pharmaceuticals' latest filing, its Profit After Tax stood at -$2.0 million for Q4 2025, which was up 2123.48% from -$1.7 million recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Profit After Tax registered a high of -$338391.0 during Q2 2023, and its lowest value of -$7.9 million during Q2 2022.
  • Moreover, its 5-year median value for Profit After Tax was -$2.1 million (2022), whereas its average is -$2.6 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first soared by 9570.03% in 2023, then crashed by 47983.84% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Profit After Tax stood at -$4.3 million in 2021, then skyrocketed by 50.94% to -$2.1 million in 2022, then grew by 29.65% to -$1.5 million in 2023, then plummeted by 74.2% to -$2.6 million in 2024, then grew by 21.23% to -$2.0 million in 2025.
  • Its Profit After Tax was -$2.0 million in Q4 2025, compared to -$1.7 million in Q3 2025 and -$1.8 million in Q2 2025.